Unicycive Therapeutics Faces Securities Fraud Lawsuit
News related to:Unicycive Therapeutics, Inc · 2 min read
LOS ANGELES, Sept. 11, 2026 /CourierPR/ -- Unicycive Therapeutics, Inc., a biotechnology company, is facing a securities fraud lawsuit from shareholders who claim to have lost money due to alleged misleading statements by the company. The lawsuit, announced by the law firm Glancy Prongay Wolke & Rotter LLP, alleges that between December 29, 2025, and June 29, 2026, the company and its executives made false and misleading statements about the company's business, operations, and prospects.
According to the complaint, Unicycive Therapeutics, Inc., failed to disclose critical information regarding its third-party manufacturing vendor's compliance with current good manufacturing practices (cGMP). Specifically, the company did not inspect the vendor's facility or conduct an audit to ensure compliance. This, the lawsuit claims, created an undisclosed risk that the U.S. Food and Drug Administration (FDA) would require additional information about the vendor's facility, potentially delaying the regulatory approval of one of the company's products, OLC.
The lawsuit asserts that these omissions and misrepresentations were material and misleading, causing investors to make decisions based on incomplete and inaccurate information. The complaint alleges that the company's positive statements about its business, operations, and prospects were not supported by a reasonable basis, thereby misleading investors.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, is now seeking to represent investors who have suffered losses due to these alleged misrepresentations. The firm is urging investors who purchased Unicycive Therapeutics, Inc., securities during the class period to contact them before November 2, 2026, to participate in the lawsuit and potentially pursue claims to recover their losses.
The law firm emphasizes its experience and success in securities litigation, noting that it was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and have represented investors and consumers in complex class action litigation.
The lawsuit is part of a broader effort to hold companies accountable for misleading statements that can harm investors. As the deadline for lead plaintiff applications approaches, investors are encouraged to act quickly to protect their rights and potentially recover their losses.